Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

QOF incentives on glycaemic control ‘improved management of type 2 diabetes’

GP practices are starting more of their newly diagnosed diabetes patients on glucose-lowering medications since the introduction of QOF indicators on tight glycaemic control, according to a report in Diabetic Medicine.

The study looked at data from the General Practice Research Database over a 10-year period between 1999 and 2008, for 21,197 patients with newly diagnosed type 2 diabetes. 

Over the five years prior to the pay-for-performance scheme, the annual rate of initiation of pharmacological treatment within 12 months of diagnosis was decreasing by 1.2% per year, whereas in the five years afterwards it went up by 1.9% year on year.

The study authors said this showed the ‘introduction of financial incentives in 2004 has effected a change in the management of people newly diagnosed with diabetes’.

The team noted that regular changes to the QOF indicators could have helped maintain the rise in treatment initiation – and there was no guarantee the trend would continue.

The researchers concluded: ‘The persistence of the change, at least within the parameters of the follow-up period, is at odds with QOF-induced changes reported in other studies and may be a consequence of the continued stimuli arising from the almost annual changes to the diabetes-related targets within the QOF.

‘It remains to be seen whether this trend will last and if further motivation may be necessary.’

Diabet Med 2014; available online 3 September

>>>> Clinical Newswire

Have your say